Eli Lilly's Mirikizumab Met The Co-primary And All Major Secondary Endpoints Compared To Placebo In The VIVID-1 Phase 3 Study For Moderately To Severely Active Crohn's Disease
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's drug, Mirikizumab, has met the co-primary and all major secondary endpoints in the VIVID-1 Phase 3 study for moderately to severely active Crohn's disease.
October 12, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Mirikizumab has shown positive results in Phase 3 trials for Crohn's disease, which could potentially lead to an increase in the company's stock price.
Positive results from a Phase 3 trial are a significant milestone for any drug. This could potentially lead to FDA approval and subsequent sales, which would increase Eli Lilly's revenues and potentially its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100